Grant: Undergraduate Student Research Awards (USRA)
University of Ottawa
$6,000.00
Manufacturing Protocol for a Fluorine-18 Protein Radiopharmaceutical Candidate
FY 2025-26
Summary
"Phosphatidylserine (PS) is a cell membrane component that is externalized during cell death pathways, including apoptosis and necrosis. PS is detected by a natural protein named annexin V, which under healthy conditions promotes efferocytosis to rapidly attenuate the PS signal. In conditions with persistent inflammation, such as atherosclerosis, infection, and cancer, ineffective efferocytosis contributes to dysregulated cell death and persistent PS signal. While researchers have crafted imaging agents to detect and characterize apoptosis for decades, none of these have yet entered clinical practice due to the complexity of their preparation and use in highly dynamic tissue environments. Our lab has developed a novel strategy for radiolabeling natural annexin V protein with the positron-emitting isotope fluorine-18 that addresses the practical challenges of previous PS-targeted imaging agents. In this proposal, we will develop radiolabeling conditions that are suitable for routine clinical production and evaluate our novel bioconjugate by small animal imaging to facilitate first-in-human studies.
Previous annexin-based imaging agents relied on inferior imaging isotopes, necessitated protein mutagenesis, and/or required multiple cumbersome synthetic steps for radiolabeling. We have developed a metalloid-mediated radiofluorination approach that is site-selective, efficient, and compatible with wild-type annexin V. We will now refine the labeling steps and conditions to define standard operating protocols to be provided to our Health Canada regulated core facility. With the labeled protein in hand, we will conduct PET imaging in rats and atherosclerotic mice to measure dosimetry and distribution.
"
Department
Program
Undergraduate Student Research Awards (USRA)
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
531019
Name
Ghedam Ezana
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Manufacturing Protocol for a Fluorine-18 Protein Radiopharmaceutical Candidate
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Ottawa
Cihramount2
$6,000
Cihrequipment2
$0
Programname2
Undergraduate Student Research Awards (USRA)
Keyworddelim
Cell; Efferocytosis; Healthy Conditions; Inflammation; Membrane; Phosphatidylserine; Protein; Rats
Abstract
"Phosphatidylserine (PS) is a cell membrane component that is externalized during cell death pathways, including apoptosis and necrosis. PS is detected by a natural protein named annexin V, which under healthy conditions promotes efferocytosis to rapidly attenuate the PS signal. In conditions with persistent inflammation, such as atherosclerosis, infection, and cancer, ineffective efferocytosis contributes to dysregulated cell death and persistent PS signal. While researchers have crafted imaging agents to detect and characterize apoptosis for decades, none of these have yet entered clinical practice due to the complexity of their preparation and use in highly dynamic tissue environments. Our lab has developed a novel strategy for radiolabeling natural annexin V protein with the positron-emitting isotope fluorine-18 that addresses the practical challenges of previous PS-targeted imaging agents. In this proposal, we will develop radiolabeling conditions that are suitable for routine clinical production and evaluate our novel bioconjugate by small animal imaging to facilitate first-in-human studies.
Previous annexin-based imaging agents relied on inferior imaging isotopes, necessitated protein mutagenesis, and/or required multiple cumbersome synthetic steps for radiolabeling. We have developed a metalloid-mediated radiofluorination approach that is site-selective, efficient, and compatible with wild-type annexin V. We will now refine the labeling steps and conditions to define standard operating protocols to be provided to our Health Canada regulated core facility. With the labeled protein in hand, we will conduct PET imaging in rats and atherosclerotic mice to measure dosimetry and distribution.
"
Competitiondate
202505
Approvedterm2
0 yr 4 mths
Pinamesdelim
Ghedam, Ezana
Approvedterm
0 an 4 mois
Cihrcontribution2
~ $6,000~ $0~